Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 14, 2013; 19(42): 7292-7301
Published online Nov 14, 2013. doi: 10.3748/wjg.v19.i42.7292
Published online Nov 14, 2013. doi: 10.3748/wjg.v19.i42.7292
Table 1 Recommended risk factor modifications in chronic pancreatitis according to the MANNHEIM criteria
Risk factor | Treatment | Comments |
Alcohol | Alcohol cessation | Decrease disease progression and may have beneficial effects on pain |
Nicotine | Smoking cessation | Decrease disease progression and may have beneficial effects on pain |
Nutritional | No specific recommendations | No prospective data |
Hereditary | Endoscopic surveillance | Currently no formal evidence, a prospective trial has been initiated |
Pancreatectomy with autolog stem cell transplantation | Preferred strategy in some United States centers | |
Efferent duct | Endoscopy or surgical interventions | The benefit of intervention is controversial |
Immunological | Steroid treatment | Treatment of autoimmune pancreatitis follows guidelines provided in e.g., Ref. 32 |
Metabolic | Lipid lowering therapy, parathyroidectomy, etc. | Consider referral to an endocrinologist |
- Citation: Olesen SS, Juel J, Graversen C, Kolesnikov Y, Wilder-Smith OH, Drewes AM. Pharmacological pain management in chronic pancreatitis. World J Gastroenterol 2013; 19(42): 7292-7301
- URL: https://www.wjgnet.com/1007-9327/full/v19/i42/7292.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i42.7292